Correction to: Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.

Abstract:

:NEDA was evaluated as the proportion of patients free of relapses, 3-month confirmed disability progression, and free of new or newly enlarging T2 lesion and Gadolinium enhancing lesions.

journal_name

CNS Drugs

journal_title

CNS drugs

authors

Papadopoulos D,Mitsikostas DD

doi

10.1007/s40263-018-0595-4

subject

Has Abstract

pub_date

2019-01-01 00:00:00

pages

93-97

issue

1

eissn

1172-7047

issn

1179-1934

pii

10.1007/s40263-018-0595-4

journal_volume

33

pub_type

已发布勘误
  • Neuroprotection in multiple sclerosis: a therapeutic approach.

    abstract::Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that is pathologically characterized by inflammatory demyelination and neurodegeneration. Axonal damage, along with neuronal loss, occurs from disease onset and may lead to progressive and permanent disability. In contrast with the inflam...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-013-0093-7

    authors: Maghzi AH,Minagar A,Waubant E

    更新日期:2013-10-01 00:00:00

  • Targeting Infectious Agents as a Therapeutic Strategy in Alzheimer's Disease.

    abstract::Alzheimer's disease (AD) is the most prevalent dementia in the world. Its cause(s) are presently largely unknown. The most common explanation for AD, now, is the amyloid cascade hypothesis, which states that the cause of AD is senile plaque formation by the amyloid β peptide, and the formation of neurofibrillary tangl...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-020-00737-1

    authors: Fülöp T,Munawara U,Larbi A,Desroches M,Rodrigues S,Catanzaro M,Guidolin A,Khalil A,Bernier F,Barron AE,Hirokawa K,Beauregard PB,Dumoulin D,Bellenger JP,Witkowski JM,Frost E

    更新日期:2020-07-01 00:00:00

  • The star systems: overview and use in determining antiepileptic drug choice.

    abstract::An explosion in antiepileptic drug (AED) therapy began in the 1990s with the licensing of 9 new chemical entities and more to come. Important differences between AEDs may not be detected by regulatory trials, which are designed to satisfy licensing requirements and often diverge considerably from everyday clinical pra...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200115010-00001

    authors: Brodie MJ,Kwan P

    更新日期:2001-01-01 00:00:00

  • Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.

    abstract:SYNOPSIS:Mirtazapine is a tetracyclic antidepressant with a novel mechanism of action; it increases noradrenergic and serotonergic neurotransmission via blockade of central α2-adrenergic auto- and heteroreceptors. The increased release of serotonin (5-hydroxytryptamine; 5-HT) stimulates serotonin 5-HT1 receptors becaus...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-199605050-00007

    authors: Davis R,Wilde MI

    更新日期:1996-05-01 00:00:00

  • The risk of stroke in patients with migraine and implications for migraine management.

    abstract::Assessing the risk of stroke in persons with migraine is complicated by the intricate relationship between these two conditions. Both migraine and stroke are common and co-morbidity may, in some cases, be coincidental. Given the overlap of clinical symptoms in stroke and migraine, each condition may also mimic the oth...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200519080-00004

    authors: Tietjen GE

    更新日期:2005-01-01 00:00:00

  • Mitoxantrone: a review of its use in multiple sclerosis.

    abstract::Mitoxantrone (Novantrone), a synthetic anthracenedione derivative, is an antineoplastic, immunomodulatory agent. Its presumed mechanism of action in patients with multiple sclerosis (MS) is via immunomodulatory mechanisms, although these remain to be fully elucidated. Intravenous mitoxantrone treatment improved neurol...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200418060-00010

    authors: Scott LJ,Figgitt DP

    更新日期:2004-01-01 00:00:00

  • Treating depression in children and adolescents: what options now?

    abstract::There have been significant developments in the understanding of depression in children and adolescents in the past few years, including an increased recognition that significant depressive illness occurs in this patient group. Pharmacological and psychotherapeutic treatments are used to manage depression in children ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200620010-00001

    authors: Varley CK

    更新日期:2006-01-01 00:00:00

  • New formulations of existing antidepressants: advantages in the management of depression.

    abstract::For nearly 50 years, antidepressant drugs have been the first-line treatment for various forms of depression. Despite their widespread use, these medications have significant shortcomings, in particular problems of patient compliance due to adverse effects. The introduction of new formulations of existing antidepressa...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200418080-00003

    authors: Norman TR,Olver JS

    更新日期:2004-01-01 00:00:00

  • Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.

    abstract::Satisfactory management of Parkinson's disease is a challenge that requires a tailored approach for each individual. In the advanced phase of the disease, patients may experience motor complications despite optimized pharmacological therapy. Apomorphine, a short-acting D1- and D2-like receptor agonist, is the only dru...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-019-00661-z

    authors: Carbone F,Djamshidian A,Seppi K,Poewe W

    更新日期:2019-09-01 00:00:00

  • Newly Approved Agents for the Treatment and Prevention of Pediatric Migraine.

    abstract::Treatment of pediatric migraine remains an unmet medical need. There continues to be a paucity of pediatric randomized controlled trials for the treatment of migraine, both in the acute and preventive settings. Pediatric studies are often complicated by high placebo-response rates and much of our current practice is b...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-016-0375-y

    authors: Kacperski J,Hershey AD

    更新日期:2016-09-01 00:00:00

  • Social anxiety disorder : current treatment recommendations.

    abstract::Social anxiety disorder (SAD) is a prevalent and disabling disorder associated with significant co-morbidity. An increased awareness of SAD over the past two decades has given impetus to advances in the pharmacotherapeutic and psychotherapeutic treatment options for this disorder. On the basis of consistent data from ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200519050-00002

    authors: Muller JE,Koen L,Seedat S,Stein DJ

    更新日期:2005-01-01 00:00:00

  • Treatment of epileptic encephalopathies.

    abstract::Epileptic encephalopathy is defined as a condition where the epileptic activity itself may contribute to the severe neurological and cognitive impairment seen, over and above that which would be expected from the underlying pathology alone. The epilepsy syndromes at high risk of this are a disparate group of condition...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-013-0041-6

    authors: McTague A,Cross JH

    更新日期:2013-03-01 00:00:00

  • Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities.

    abstract::Progress in finding a better alternative to alteplase has been slow. Tenecteplase and desmoteplase have better pharmacological profiles compared with alteplase, but definite clinical evidence of their superiority is lacking. The two major phase III studies that have tested the efficacy and safety of desmoteplase in is...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-015-0307-2

    authors: Logallo N,Kvistad CE,Nacu A,Thomassen L

    更新日期:2016-02-01 00:00:00

  • Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes.

    abstract::Biopharmaceuticals can induce antibodies, which interact with and neutralize the therapeutic effect of such drugs and are therefore termed neutralizing antibodies (NAbs). In the treatment of multiple sclerosis, NAbs against interferon (IFN)-beta and natalizumab have been recognized. The prevalence of NAbs against diff...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200923050-00003

    authors: Deisenhammer F

    更新日期:2009-01-01 00:00:00

  • Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.

    abstract::Statins, or 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, such as lovastatin, atorvastatin, simvastatin, pravastatin, fluvastatin, rosuvastatin and pitavastatin, are cholesterol-lowering drugs used in clinical practice to prevent coronary heart disease. These drugs are generally well tolerated and have ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-013-0135-1

    authors: Tuccori M,Montagnani S,Mantarro S,Capogrosso-Sansone A,Ruggiero E,Saporiti A,Antonioli L,Fornai M,Blandizzi C

    更新日期:2014-03-01 00:00:00

  • Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.

    abstract:BACKGROUND:Several small studies have shown beneficial effects of ondansetron, a serotonin 5-HT(3) receptor antagonist, in the treatment of obsessive-compulsive disorder (OCD). The efficacy of other 5-HT(3) receptor antagonists in patients with OCD is still unclear. Granisetron does not alter cytochrome P450 activity a...

    journal_title:CNS drugs

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.2165/11635850-000000000-00000

    authors: Askari N,Moin M,Sanati M,Tajdini M,Hosseini SM,Modabbernia A,Najand B,Salimi S,Tabrizi M,Ashrafi M,Hajiaghaee R,Akhondzadeh S

    更新日期:2012-10-01 00:00:00

  • Methylene Blue in the Treatment of Neuropsychiatric Disorders.

    abstract::Methylene blue is a long-established drug with complex pharmacology and multiple clinical indications. Its diverse mechanisms of action are most likely responsible for the large variety of its clinical effects. Of interest to psychiatrists, methylene blue has antidepressant, anxiolytic, and neuroprotective properties ...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-019-00641-3

    authors: Alda M

    更新日期:2019-08-01 00:00:00

  • A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease.

    abstract:INTRODUCTION:Intranasal (IN) insulin acutely improves verbal memory in mild cognitive impairment (MCI)/Alzheimer's disease (AD), but its therapeutic effects may be attenuated in apolipoprotein E4 (ApoE4) carriers. Furthermore, rapid-acting (RA) insulins may have superior therapeutic effects compared with regular insuli...

    journal_title:CNS drugs

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40263-014-0214-y

    authors: Rosenbloom MH,Barclay TR,Pyle M,Owens BL,Cagan AB,Anderson CP,Frey WH 2nd,Hanson LR

    更新日期:2014-12-01 00:00:00

  • Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study.

    abstract:BACKGROUND:Earlier commencement of clozapine has been related to a better response in treatment-resistant schizophrenia. OBJECTIVES:To identify variables that predict clozapine use after a first episode of schizophrenia (FES). METHODS:Patients with FES and ≤15 days of lifetime antipsychotic treatment were followed up...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-016-0358-z

    authors: Üçok A,Çıkrıkçılı U,Ergül C,Tabak Ö,Salaj A,Karabulut S,Correll CU

    更新日期:2016-10-01 00:00:00

  • Affective disorders in patients with HIV infection: impact of antiretroviral therapy.

    abstract::At the beginning of the AIDS pandemic, affective disorders (such as depressed mood) were seen in a considerable number of HIV-1-infected individuals. These disorders were a result of the poor physical condition of the patients, brain involvement by the virus (e.g. encephalopathy) or a reaction to disadvantageous livin...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200620060-00005

    authors: Arendt G

    更新日期:2006-01-01 00:00:00

  • Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.

    abstract::The link between diabetes mellitus and Alzheimer's disease (AD) has been known for the last few decades. Since insulin and insulin receptors are known to be present in the brain, the downstream signalling as well as the effect of hyperinsulinemia have been extensively studied in both AD and Parkinson's disease. Glucag...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-015-0301-8

    authors: Calsolaro V,Edison P

    更新日期:2015-12-01 00:00:00

  • Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update.

    abstract::Glutamatergic, noradrenergic, serotonergic, and cholinergic systems play a critical role in the basal ganglia circuitry. Targeting these non-dopaminergic receptors remains a focus of ongoing research to improve Parkinson's disease (PD) motor symptoms, without the potential side effects of dopamine replacement therapy....

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00754-0

    authors: Gonzalez-Latapi P,Bhowmick SS,Saranza G,Fox SH

    更新日期:2020-10-01 00:00:00

  • Genetic Influence on Efficacy of Pharmacotherapy for Pediatric Attention-Deficit/Hyperactivity Disorder: Overview and Current Status of Research.

    abstract::Multiple stimulant and non-stimulant medications are approved for the treatment of attention-deficit/hyperactivity disorder (ADHD), one of the most prevalent childhood neurodevelopmental disorders. Choosing among the available agents and determining the most effective ADHD medication for a given child can be a time-co...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-020-00702-y

    authors: Elsayed NA,Yamamoto KM,Froehlich TE

    更新日期:2020-04-01 00:00:00

  • Potential of Glial Cell Modulators in the Management of Substance Use Disorders.

    abstract::The pervasive and devastating nature of substance use disorders underlies the need for the continued development of novel pharmacotherapies. We now know that glia play a much greater role in neuronal processes than once believed.  The various types of glial cells (e.g., astrocytes, microglial, oligodendrocytes) partic...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-020-00721-9

    authors: Jones JD

    更新日期:2020-07-01 00:00:00

  • The glutamatergic system and Alzheimer's disease: therapeutic implications.

    abstract::Alzheimer's disease affects nearly 5 million Americans currently and, as a result of the baby boomer cohort, is predicted to affect 14 million Americans and 22 million persons totally worldwide in just a few decades. Alzheimer's disease is present in nearly half of individuals aged 85 years. The main symptom of Alzhei...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200317090-00004

    authors: Butterfield DA,Pocernich CB

    更新日期:2003-01-01 00:00:00

  • Secondary Progressive Multiple Sclerosis: Definition and Measurement.

    abstract::Secondary progressive multiple sclerosis (SPMS) is diagnosed retrospectively and involves a clinical course characterized by a progressive accumulation of neurological disability, independent of relapses, following an initial relapsing-remitting (RR) phase. Our incomplete understanding of the pathological mechanisms u...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40263-016-0340-9

    authors: Plantone D,De Angelis F,Doshi A,Chataway J

    更新日期:2016-06-01 00:00:00

  • Clinically important drug interactions with zopiclone, zolpidem and zaleplon.

    abstract::Insomnia, an inability to initiate or maintain sleep, affects approximately one-third of the American population. Conventional benzodiazepines, such as triazolam and midazolam, were the treatment of choice for short-term insomnia for many years but are associated with adverse effects such as rebound insomnia, withdraw...

    journal_title:CNS drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00023210-200317070-00004

    authors: Hesse LM,von Moltke LL,Greenblatt DJ

    更新日期:2003-01-01 00:00:00

  • A Retrospective Cohort Study of Acute Kidney Injury Risk Associated with Antipsychotics.

    abstract:BACKGROUND:A recent large database analysis raised concerns of potential acute kidney injury (AKI) risk associated with antipsychotics. However, whether individual atypical and typical antipsychotics are associated with differential AKI risks has not been investigated. OBJECTIVE:The current study compared the risks of...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-017-0421-4

    authors: Jiang Y,McCombs JS,Park SH

    更新日期:2017-04-01 00:00:00

  • Restoring Function to Dopaminergic Neurons: Progress in the Development of Cell-Based Therapies for Parkinson's Disease.

    abstract::There is escalating interest in cell-based therapies to restore lost dopamine inputs in Parkinson's disease. This is based upon the rationale that implanting dopamine progenitors into the striatum can potentially improve dopamine-responsive motor symptoms. A rich body of data describing clinical trials of previous cel...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.1007/s40263-020-00727-3

    authors: Henchcliffe C,Sarva H

    更新日期:2020-06-01 00:00:00

  • Mixed Anxiety and Depression : Diagnosis and Treatment Options.

    abstract::Symptoms of anxiety and depression often appear together in patients, either as 2 discrete disorders, such as major depressive disorder and panic disorder, or as a combination of symptoms not meeting criteria for specific disorders. The social, economic, occupational and medical costs of such comorbid anxiety and depr...

    journal_title:CNS drugs

    pub_type: 杂志文章

    doi:10.2165/00023210-199809040-00003

    authors: Bakish D,Habib R,Hooper CL

    更新日期:1998-04-01 00:00:00